Shenzhen Yimin Biopharmaceutical Technology Co., Ltd (hereinafter referred to as “Shenzhen Yimin”) was founded in 2022 and specializes in stem cell research and application. The company helps its customers improve the efficiency of stem cell product development and provides patients with customized cell and gene therapy solutions. The company is based on the research team of Dr. Sun Yi from Tongji University, which also collaborates with Tongji University School of Medicine, Shanghai Tongji Hospital, Shanghai East Hospital, Chinese Academy of Sciences, and Ai Kang Biology. The company’s business covers cell testing, cell storage, body immunology testing, and personalized regenerative therapy. Core Technology

Autologous Rejuvenated Cells

ARC: Autologous Rejuvenated Cells

Shenzhen Yimin’s core technology is the autologous rejuvenation cell technology developed by Dr. Sun Yi’s team through many years of research in cell therapy. Through a unique in vitro culture and small molecule induction system, this technology can rejuvenate human skin fibroblasts of any age, turning them into autologous cells with powerful immune-regulating and nutritional functions. These cells are injected into the body through intravenous infusion and have the effect of prolonging life and rejuvenating various organs. Independent third-party testing has confirmed that autologous rejuvenated cells (ARC) are an effective treatment for age-related diseases such as osteoporosis, muscle atrophy, osteoarthritis, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS), for which there are currently no solutions. This technology also helps strengthen the immune system and has shown significant results in prolonging lifespan.

Professor Sun Yi is the director of the Stem Cell Clinical Translation Center of Tongji Hospital.

Executive Director of the International Center for Stem Cell and Regenerative Medicine certified by the Ministry of Science and Technology of China.

Executive Director of the Shanghai Institute for Clinical Translation of Stem Cells She has received many awards, including the Alfred P. Sloan Research Award (Alfred P. Sloan Fellow), Beckman Young Investigator Award (Beckman Young Investigator Award), Whitehall Foundation Research Award (Whitehall Foundation Research Award), Stein-Oppenheimer Award (Stein-Oppenheimer Foundation Award), Klingenstein Neuroscience Award (Klingenstein Neuroscience Research Award), Shanghai International Science and Technology Award, Shanghai First Science and Technology Award, Shanghai First Gold Science and Technology Award and more.

Professor Yi Sun has led projects funded by the US National Institutes of Health (NIH), the US Alliance for Schizophrenia and Depression Research, the Arnold and Mabel Beckman Foundation, the Rett Syndrome Research Foundation, the Science Creation Foundation of China (NSFC) Key International Projects, Key Projects, the Ministry of Health Science and Technology of China Key Research Programs with a total research budget exceeding 100 million RMB. She has published 114 articles in SCI journals with a total impact factor of over 1500 and a h-index (H-index) of 62. The total citation volume is 20,367 times. Her publications include 5 articles in Cell, 2 articles in Nature, 3 articles in Science, 4 articles in Neuron, 4 articles in Nature Neuroscience, 2 articles in Nature Communications, 1 article in Cancer Cell, 1 article in Cell Stem Cell, 1 article in Molecular Cell, 1 article in Nature Medicine, 1 article in Cell Research, 17 articles in PNAS. She holds 14 patents, including inventions (granted or pending).